Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that the National Institutes of Health (NIH) has awarded up to $15.6 million over 5 years in grants to The University of North Carolina, Chapel Hill (UNC-CH) and The University of Colorado, Denver (UCD) to conduct research with mucolytic agents discovered by Parion Sciences and to enable Investigational New Drug (IND) applications for Parion’s molecules.
The first year of funding awarded for the Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Disease (CADET) grant awards include $1.46 million ($7.7 million total) to UNC-CH to conduct pre-clinical research on Parion’s mucolytic program in the areas of Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF). The second CADET grant was awarded to UCD for $1.52 million in the first year ($7.9 million total) in support of pre-clinical research on Parion’s mucolytic program in Idiopathic Pulmonary Fibrosis (IPF). The two grants will be utilized over a total of 5 years with a renewal after the first 2 years and annual reviews.
Parion Sciences is a development stage company dedicated to research, development, and commercialization of treatments to restore patient’s innate mucosal surface defenses. They design and testing novel mucolytic agents that specifically target mucus structure to facilitate mucus clearance from the lungs. There is a need for agents that clear adherent secretions from the lungs in acute and chronic pulmonary disorders.
If approved by the FDA, the agents will become drugs aimed at dramatically improving the lives of millions of people who suffer from COPD, CF, and IPF.
Parion has also been funded by the Cystic Fibrosis Foundation Therapeutics, as well as other organizations. Last September, the foundation awarded the company a $3 million donation to help further their research on the genetic and chronic disease. Parion’s CF candidate treatment, P-1037, an epithelial sodium channel (ENaC) inhibitor, designed to stimulate secretion of fluid along the lungs’ mucosal surface, is expected to run phase II of clinical trials in 2014.
This is good news for the CF community in advancing new treatments that help to restore proper lung function and innate mucosal defense systems.
Source: http://t.co/9GaqZeDPgb
(Added 19 Oct 2014) Follow up press release with additional information: http://t.co/xf6KHf0OYQ
- Chris
The first year of funding awarded for the Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Disease (CADET) grant awards include $1.46 million ($7.7 million total) to UNC-CH to conduct pre-clinical research on Parion’s mucolytic program in the areas of Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF). The second CADET grant was awarded to UCD for $1.52 million in the first year ($7.9 million total) in support of pre-clinical research on Parion’s mucolytic program in Idiopathic Pulmonary Fibrosis (IPF). The two grants will be utilized over a total of 5 years with a renewal after the first 2 years and annual reviews.
Parion Sciences is a development stage company dedicated to research, development, and commercialization of treatments to restore patient’s innate mucosal surface defenses. They design and testing novel mucolytic agents that specifically target mucus structure to facilitate mucus clearance from the lungs. There is a need for agents that clear adherent secretions from the lungs in acute and chronic pulmonary disorders.
If approved by the FDA, the agents will become drugs aimed at dramatically improving the lives of millions of people who suffer from COPD, CF, and IPF.
Parion has also been funded by the Cystic Fibrosis Foundation Therapeutics, as well as other organizations. Last September, the foundation awarded the company a $3 million donation to help further their research on the genetic and chronic disease. Parion’s CF candidate treatment, P-1037, an epithelial sodium channel (ENaC) inhibitor, designed to stimulate secretion of fluid along the lungs’ mucosal surface, is expected to run phase II of clinical trials in 2014.
This is good news for the CF community in advancing new treatments that help to restore proper lung function and innate mucosal defense systems.
Source: http://t.co/9GaqZeDPgb
(Added 19 Oct 2014) Follow up press release with additional information: http://t.co/xf6KHf0OYQ
- Chris